CG1xCD3e

CG1xCD3e is a novel T-cell receptor mimic (TCRm) bispecific antibody designed for the treatment of acute myeloid leukemia (AML). It targets the CG1 peptide (FLLPTGAEA), a leader sequence-derived peptide from Cathepsin G (CG) presented on HLA-A*0201. Cathepsin G is a serine protease overexpressed in AML blasts compared to normal myeloid progenitors. The antibody utilizes a TCRm construct to recognize the intracellular antigen presented as a peptide/HLA complex on the cell surface. The bispecific molecule incorporates an anti-CD3e scFv (using Xencor's xMab platform) to recruit and activate T cells against CG1-expressing leukemia cells. Developed by researchers at the University of Texas MD Anderson Cancer Center in collaboration with Alloy Therapeutics, CG1xCD3e has demonstrated potent T-cell dependent cellular cytotoxicity (TDCC) and anti-leukemia activity in preclinical models, including significant reduction of leukemia burden in NSG mice.

Other names

CG1-targeting T cell-engager bispecific antibodyCG-1-targeting T cell-engager bispecific antibodyCG 1-targeting T cell-engager bispecific antibodyCG1/HLA-A2 x CD3 bispecific antibody